EW Stock Up 5.9% after 5-Day Win Streak
Edwards Lifesciences (EW) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 4.5% return. The company has gained about $2.0 Bil in value over the last 5 days, with its current market capitalization at about $45 Bil. The stock remains 5.6% above its value at the end of 2024. This compares with year-to-date returns of 5% for the S&P 500.
Comparing EW Stock Returns With The S&P 500
The following table summarizes the return for EW stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | EW | S&P 500 |
|---|---|---|
| 1D | 1.4% | 0.5% |
| 5D (Current Streak) | 5.9% | 3.4% |
| 1M (21D) | 2.0% | 4.8% |
| 3M (63D) | 9.9% | 8.4% |
| YTD 2025 | 5.6% | 5.0% |
| 2024 | -2.9% | 23.3% |
| 2023 | 2.2% | 24.2% |
| 2022 | -42.4% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 64 S&P constituents with 3 days or more of consecutive gains and 23 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 8 | 13 |
| 4D | 5 | 9 |
| 5D | 19 | 1 |
| 6D | 11 | 0 |
| 7D or more | 21 | 0 |
| Total >=3 D | 64 | 23 |
Key Financials for Edwards Lifesciences (EW)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $5.0 Bil | $5.4 Bil |
| Operating Income | $1.5 Bil | $1.5 Bil |
| Net Income | $1.4 Bil | $4.2 Bil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $1.4 Bil | $1.4 Bil |
| Operating Income | $353.3 Mil | $409.9 Mil |
| Net Income | $385.6 Mil | $358.0 Mil |
While EW stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.